Pregnancy Outcomes Related to Mycophenolate Exposure in Female Kidney Transplant Recipients

In 2012, the U.S. Food and Drug Administration issued guidelines advising kidney transplant recipients (KTRs) to discontinue mycophenolate (MPA) in preparation for pregnancy. Little is known about how this guidance has affected pregnancy and graft outcomes. The purpose of this retrospective cohort s...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of transplantation 2017-01, Vol.17 (1), p.151-160
Hauptverfasser:	King, R. W., Baca, M. J., Armenti, V. T., Kaplan, B.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult antiproliferative agent: mycophenolate mofetil (MMF) antiproliferative agent: mycophenolate sodium Birth Birth defects clinical research/practice Congenital defects drug toxicity enteric coated Female Fetuses Follow-Up Studies Glomerular Filtration Rate Graft Rejection - drug therapy Graft Rejection - etiology graft survival Graft Survival - drug effects Health risk assessment Humans immunosuppressant Immunosuppressive Agents - therapeutic use Kidney Failure, Chronic - surgery Kidney Function Tests Kidney transplantation Kidney Transplantation - adverse effects kidney transplantation/nephrology Kidney transplants Miscarriage Mycophenolic acid Mycophenolic Acid - therapeutic use obstetrics and gynecology pharmacology Postpartum Pregnancy Pregnancy Outcome Retrospective Studies Risk Factors Transplant Recipients Transplants & implants Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!